Molecular analysis of potentially actionable mutations has become routine practice in oncological pathology. However, testing a wide range of oncogenes and mutations can be technically challenging because of limitations associated with tumor biopsy. Circulating tumor DNA (ctDNA) is a potential tool for the noninvasive profiling of tumors. In this study, we developed a next-generation sequencing (NGS)-based test for the detection of clinically relevant mutations in ctDNA and evaluated the feasibility of using this ctDNA NGS-based assay as an alternative to tissue genotyping. Tissue and matched blood samples were obtained from 72 patients with advanced nonsmall cell lung cancer (NSCLC). NGS-based testing was performed using plasma cell-free DNA (cfDNA) samples of all 72 *These authors contribute equally to this study. patients as well as tumor DNA samples of 46 patients. Of the remaining 26 patients, tDNA was tested by amplification refractory mutation system PCR (ARMS-PCR) because of insufficient tissue sample or quality for NGS. Of the 46 patients who had tDNA and cfDNA NGS performed, we found 20 patients were concordant between tDNA and ctDNA alterations and 21 sample pairs were discordant because of additional alterations found in tDNA. Considering all clinically relevant alterations, the concordance rate between tDNA and ctDNA alterations was 54.9% with a sensitivity of 53.2% and a specificity of 75.0%. Our findings demonstrate that targeted NGS using cfDNA is a feasible approach for rapid and accurate identification of actionable mutations in patients with advanced NSCLC, and may provide a safe and robust alternative approach to tissue biopsy.
| I N TR ODU C TI ON
Lung cancer is the leading cause of cancer-related mortality in the world. 1 In China, the mortality of lung cancer increased dramatically in the last three decades. 2 Targeted therapeutics have shown considerably better clinical efficacy compared with standard therapy in patients with nonsmall cell lung cancer (NSCLC) and an oncogenic mutation. [3] [4] [5] [6] Of these cases, most were adenocarcinoma in which an increasing number of oncogenic driver mutations have been discovered in recent years. In the latest version of the National Comprehensive Cancer Network (NCCN), EGFR, ALK, and ROS1 testing were recommended before making therapy decisions.
Additionally, emerging targeted drugs were listed for genetic alterations including BRAF V600E, MET amplification or the exon 14 skipping mutation, RET rearrangements, and HER2 mutations. 7 As there is a steady increase in the number of targeted genes through existing genotypeselected trials, the capacity for multiplexing detection will become crucial and even indispensable in the near future. Thus, a platform such as nextgeneration sequencing (NGS) that enables the detection of multiple tumor-specific mutations in a single assay is urgently needed.
Tissue biopsy is the gold standard for molecular testing, yet poor quality and inadequate quantity of tissue obtained makes the test inaccessible to approximately 20-30% patients when tissue is obtained from core needle biopsies. 8 In contrast, liquid biopsy could address this issue
given the relative ease of blood collection that is much safer and less stressful for the patient. Moreover, there are several other advantages of testing circulating tumor DNA (ctDNA) over tissue biopsy: (1) rebiopsy is not always feasible with tissue, but ctDNA is accessible during the entire disease course; (2) identify treatment resistance by the detection of resistant clones that could be used to guide the subsequent treatment at disease progression and explore mechanism of novel resistance; and (3) regarding cost effectiveness and turnaround time, liquid biopsy is faster and can cost significantly less than tissue biopsy considering the full cost in obtaining tissue samples and the potential extra costs caused by biopsy complications. 9 With growing evidence demonstrating the reliability of ctDNA in genetic profiling, the Food and Drug Administration (FDA) from the United States approved the Cobas EGFR Mutation Test v2 as a companion diagnostic kit for NSCLC in June 2016.
A meta-analysis concluded that ctDNA testing showed high diagnostic accuracy; however, the sensitivity varies considerably depending on the platform and detection method. 10 Further, challenges remain in using ctDNA for liquid biopsy testing because of the inherently ultra-low concentration of ctDNA found in peripheral blood. 11 Thus, NGS sequencing procedures and variant calling strategies must be improved to detect low abundancy mutations while avoiding false positive results. Previous studies have specifically focused on the detection of a single biomarker or a few hotspot mutations such as EGFR mutations using single nucleotide variants (SNVs) or insertion/deletions (indel). The purpose of this study was to evaluate the detection performance of four types of variants in ctDNA on an ion proton platform using matched tumor DNA (tDNA) and cell-free DNA (cfDNA) from plasma of patients with advanced NSCLC.
| M A TER I A LS A N D M ETH OD S

| Ethics statement and patients
The study was approved by the Institutional Review Board of the Beijing Genomics Institute. All 72 patients who participated in this study provided written informed consent for the use of blood and lung tumor tissue. Patients were eligible for the study if they were diagnosed with advanced NSCLC using tissue biopsy and extra blood and tumor tissue samples were available for NGS testing ( Figure 1 for the detection of four types of actionable variants in plasma, specifically SNVs, indels, rearrangements, and copy number variations (CNVs).
First, reference sequences aimed at the hotspot mutations were assembled, then reads were mapped to the new assembled reference to precisely distinguish the supporting reads. Moreover, log odds (LOD) and Poisson mathematical model were integrated to control sequencing errors. As a result, VHVT can achieve a limitation of detection at 0.01% with sensitivity and specificity above 95% and 99%, respectively.
Detailed information regarding this software can be found in an ASCO Abstract we reported previously. 13 Rearragements were detected using 
| Mutation validation by digital PCR
Digital PCR (dPCR) was carried out to confirm the identification of hotspot mutations in tDNA that were absent in plasma cfDNA via NGS.
Mutant allele frequency was measured using the QuantStudio 3D Digital PCR System (Thermo Fisher) and QuantStudio 3D Digital PCR 20K
Chip Kit v2 in accordance with the manufacturer's instructions. Briefly, 5-10 ng of cfDNA was added to dPCR reaction mixtures containing primers and probe. The dPCR reaction was performed with the following conditions: 1 cycle of 968C for 10 min followed by 39 cycles of 568C for 2 min and 988C for 30 s, 1 cycle of 608C for 2 min, and 1 cycle of 108C for 10 min. dPCR data were analyzed using QuantStudio 3D
Analysis Suite Software (Thermo Fisher). Measures of TP, TN, FN, and FP were used to calculate sensitivity, specificity, and concordance rate.
| Statistical analysis
All statistical analyses were two sided and a P < .05 was considered statistically significant. Analyses were performed using R 3.3. adenocarcinoma histological subtype (n 5 63, 87.5%), and the remaining patients (n 5 9) had a diagnosis of either a squamous cell histological subtype (n 5 3, 4.2%) or NSCLC-not otherwise specified (n 5 6, 8.3%) ( Table 1) . At the time of diagnosis, 58 patients whose cancer was staged were at either stage III (31.9%) or stage IV (48.6%).
| RE S U L TS
| Patient characteristics
| Assay performance assessed by cell lines
Cell lines with known variants H1975 (EGFR L858R and T790M), PC-9
(EGFR p.E746-A750del), H2228 (ALK-EML4), HCC78 (ROS1_SLC34A2), and SNU (MET amplification) were diluted to assess the analytical sensitivity and limit of detection (LOD) for the different variant types (SNV, indel, CNV, and rearrangement). We mixed DNA from mutated cell lines with DNA from wildtype cell lines to derive various target allele frequencies (30%, 10%, 5%, 1%, and 0.5%). Based on the established sequencing coverage (3800-31000), the LOD was determined using a mathematical model and then validated on DNA dilutions derived from cell lines (Supporting Information Table S1 ). The LOD was defined as a mutation frequency that can be successfully detected greater than 95% chance. For SNVs and indels, we determined the analytical sensitivity as 100% at a LOD of 1%. At an allele frequency of 0.5%, 15/16 (93.8%) SNVs and 6/6 (100%) indels were detected. Regarding rearrangements and CNVs, we detected all mutations with an allele frequency 10% (Supporting Information Table S1 ).
The measured allele frequency was in accordance with the expected allele frequency. We found that the assay showed a good inter-run reproducibility when assessed using eight samples harboring three mutations with an allele frequency of 1% (Supporting Information   Table S2 ). While reads containing SNVs and short indels can be mapped to the right position using Gatk-like programs, a program designed for germline mutation detection and widely used for somatic mutation detection, reads containing long indels, such as EGFR EX19
deletions are often wrongly mapped especially when there are deletions near the ends of the reads. Thus, Gatk did not recognize these reads, consequently underestimating the mutation allelic frequency, and even missed out indels when supporting reads were rare. These findings demonstrated that a high analytical performance was achieved using VHVT, 13 which unlike other toolkits, shows an outstanding capacity to discriminate reads, and thus, enables the detection of actionable EGFR EX19 deletions.
| cfDNA concentration and clinical relevance
Of the 72 plasma samples collected, the median cfDNA concentration in plasma was 15.32 ng/mL (IQR 5 9.26 ng/mL). cfDNA concentration was not significantly associated with metastasis status, although we observed that cfDNA concentrations were slightly higher in patients with metastasis (median concentration of 13.25 vs. 16 .98 ng/mL, respectively) (Supporting Information Table S3 ). We also found that cfDNA concentrations
were not significantly associated with gender. The median concentration was 13.16 ng/mL in males and 16.66 ng/mL in females (P 5 .063). Abbreviations: ADC, adenocarcinoma; NA, not available; NOS, not otherwise specified; SCC, squamous cell carcinoma.
| Somatic mutations detected in tumor samples by NGS
EML4-ALK rearrangement, which is sensitive to the ALK tyrosinekinase inhibitor (TKI) crizotinib, and one patient had a RET rearrangement, which is sensitive to cabozantinib. In addition, we detected KRAS mutations in six plasma samples and BRAF V600E and EGFR L861R in one sample each. The KRAS mutations included G12A, G12C, and G12R, variants associated with original resistance to EGFR TKI in lung cancer. We found no co-occurring mutations in any of the plasma samples tested.
| Concordance between tumor and plasma results
We compared clinically relevant genomic alterations for 46 patients (68%) in our 72-patient cohort who had both tDNA and cfDNA NGS performed ( Figure 2 ). We found that 20 patients have concordant tDNA and cfDNA alterations, and 5 patients have no alterations in either tDNA or plasma cfDNA. Of these 20 concordant sample pairs, the average allele frequency of mutations in tDNA was significantly greater than that found in plasma cfDNA (26.9% vs. 7.4%, P < .001).
The remaining 21 sample pairs were discordant because additional alterations were found in tDNA. We found a significant positive correlation between tumor and cfDNA variant allele frequency (Spearman r 5 0.44, P 5 .027).
Considering all clinically relevant alterations, the concordance rate between tDNA and cfDNA alterations was 54.9% with a sensitivity of 53.2%, specificity of 75.0%, and a plasma positive predictive value of 96.2%. For tDNA and plasma cfDNA from the 19 patients with metastasis, the alteration concordance rate was 65%. On the other hand, the 19 samples from primary patients had a mutation concordance of 50%.
We also studied concordance for the most frequent alterations for all 72 patients who have both tDNA (NGS or routine methods) and cfDNA NGS results. Using tDNA as reference, we found that the 
| dPCR validation
All 21 patients with discordant results were positive on tumor and negative on plasma. To exclude FN results generated by NGS in plasma samples, of which most were SNVs and indels, dPCR was performed to 10 samples. We found one sample was positive using dPCR for EGFR L858R with a mutant allele frequency of 0.49%. Other discordant samples were not validated by dPCR because of sample insufficiency. Further, CNVs and rearrangements could not be validated because methods such as quantitative PCR require a significant amount of DNA, which is not available when using cfDNA.
| D ISC USSION
In this study, we evaluated NGS performance using a Beijing Genomics Institute (BGI) lung cancer panel on the Ion Proton Platform for the detection of gene mutations in cfDNA. To our knowledge, this is the first study to assess the performance of the Ion Proton for the detection of four distinct types of variants in cfDNA. Our assay had an overall sensitivity of 53.2% when all detected mutations were considered.
Mutations in plasma samples were all identified in tumor samples, whereas 24 mutations identified in tumor tissue samples were FN using plasma. Among the 24 FN mutations, we found that 11 were SNVs, 7 were EGFR exon 19 deletions, 4 were CNVs, and 2 were rearrangements. Further, material was available for dPCR in 10 samples.
Analysis of plasma samples with dPCR only confirmed the presence of a mutation in one case, which was EGFR L858R with a mutant allele frequency of 0.49%. Our findings using dPCR in NGS-negative plasma samples revealed that the variants found in tumor were likely either not shed into the circulation or were present at an ultra-low level that was beyond our limit of detection, which was set at 1% for SNVs and indels. Among the 21 discordant samples, we found in addition to EGFR mutations that four samples had co-occurring mutations in tumor
tissues, yet only EGFR L858R was detected in matched plasma samples.
The two cases with co-occurrence of EGFR and KRAS mutations in tumor tissue are rare, and NGS results were confirmed in tumor tissue by dPCR. Furthermore, we also did not detect the four cases of MET amplification in cfDNA that were found by NGS using tDNA. MET amplification is associated with gefitinib resistance in patients with lung cancer and MET targeted therapy has received preclinical and clinical trials. 16, 17 Identifying MET amplification in patients with lung cancer could aid the development of personalized medicine by identifying those patients who will benefit from treatment with MET inhibitors. Several studies, which have mostly focused on EGFR mutations, have reported different sensitivities for the detection of gene mutations in plasma cfDNA using different detection approaches. In one study, the sensitivity and specificity for EGFR mutation detection using droplet digital PCR (ddPCR) were reported to be 81.82% and 98.44%
respectively, 23 whereas another study found a sensitivity of 65.7% and a specificity of 99.8% with Scorpion ARMS using the Therascreen kit (Qiagen), 24 which is the most frequently used method. The sensitivity of detecting EGFR mutations in plasma cfDNA using an NGS-based approach was comparable to that found using other methods. A metaanalysis of 27 studies using NGS reported a sensitivity and specificity of 62.0% and 95.9%, respectively. 10 In our study, we found a sensitivity and specificity of 68.4% and 100%. However, a limitation of ddPCR In the present study, 21 sample pairs were discordant with all alterations identified in specifically tDNA. The discordance may be due to the low concentration of ctDNA found in plasma, which results in a lower mutation frequency in plasma cfDNA than in tissue DNA. The results of dPCR partly supported this our assumption.
Among 10 cases with mutations in tDNA only, merely one plasma was found positive using dPCR with a mutant allele frequency of 0.49%, indicating the mutations were either not shed into blood or the concentration of the mutation is below the detection limit of our method. In addition, our assay may not be sufficiently sensitive to detect very low frequency alterations that may be more readily identified by testing tissue, especially towards detection of CNVs and gene arrangements. In our matched sample pairs, four discordant samples have either a MET or HER2 CNV in tDNA, but none was detected in the corresponding cfDNA samples (Supporting Information Figures S3 and S4) .
Previous research has shown that the proportion of ctDNA in plasma varies by tumor size, disease stage, and the number of metastatic sites. 26, 27 Similarly, our results show that M1 stage patients have higher concordance than M0 stage patients. These results suggest that the amount of cfDNA may reflect tumor burden and could be a biomarker for disease monitoring.
Clinically actionable alterations found in plasma cfDNA can also assist in guiding the selection of targeted therapies. Actionable alterations included in guidelines from the NCCN, AMP, ASCO, and CAP were found in 39 patients with lung cancer (54.2%) in our cohort (Table   5 ). Furthermore, EGFR alterations (L858R and exon 19 del) were the most frequent alterations found in cfDNA from 26 plasma samples in our study, both of which are actionable with approved EFGR TKIs (erlotinib, gefitinib, and afatinib). 3, 6, 28 Previous studies reported that EGFR mutations are predominantly observed in nonsquamous NSCLC, in patients who are nonsmokers, and in Asian patients. 29 In the current study, we observed a putatively significant difference between EGFR mutations and smoking status (P 5 .057). Additionally, drug resistance is a major clinical problem in patients responsive to EGFR-TKIs. An understanding of the molecular mechanisms responsible for acquired resistance is crucial including the development of primary resistance and the role of acquired mutations in EGFR (T790M and the exon 21 insertion) and in other oncogenes, such as BRAF, PIK3CA, HER2, and MET. 30, 31 In our study, one EGFR exon 21 insertion and six KRAS activating mutations detected in cfDNA were previously associated with either a much lower response or acquired resistance to TKIs. No other acquired resistance mutation was found in our patient cohort. For inclusion in our study, these patients did not receive EGFR TKI-based therapy, which demonstrates the urgent need to provide a cfDNA test for actionable mutations early to patients with lung cancer to ensure they receive effective and timely personalized treatment.
In conclusion, we successfully developed a ctDNA NGS assay and analysis pipeline that can be used to detect cancer-related mutations and rearrangements in plasma samples obtained from patients with advanced NSCLC. Our results showed high concordance in the detection of clinically actionable alterations found in tumor tissues and paired plasma samples. In addition, we found that concordance rate is associated with cancer stage and tumor aggressiveness. Our ctDNA NGS test has great prospects for mutation profiling in patients who are unable to provide a histological sample, and may be a less invasive, more comprehensive, and cost-effective approach to identify targeted therapeutic strategies and monitor treatment response in patients with lung cancer. 
